Last reviewed: July 8, 2026
Last updated: July 8, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Wegovy, the brand-name version of semaglutide, follows a strict 16-week titration protocol that starts with the lowest dose of 0.25 milligrams injected once per week. This gradual escalation helps minimize gastrointestinal side effects while your body adapts to the medication. Many patients seek lower-cost alternatives that follow similar evidence-based dosing principles.
Understanding Wegovy's Lowest Starting Dose
The entry-level dose for Wegovy is 0.25 mg administered as a subcutaneous injection once weekly. This modest starting amount allows clinicians to assess individual tolerance before advancing to higher concentrations. Clinical trials showed that even this minimal dose produces meaningful appetite suppression and weight reduction in most patients during the first four weeks.
Starting low serves a critical clinical purpose: it reduces the likelihood of nausea, vomiting, constipation, and other gastrointestinal effects that can cause treatment discontinuation. Your body's GLP-1 receptors—located throughout your digestive system and brain—need time to acclimate to medication signaling. Ramping up too quickly can overwhelm this system and lead to side effects that feel unbearable.
The 16-Week Wegovy Titration Schedule
Wegovy follows a standardized four-step titration ladder over 16 weeks. Weeks 1–4 use 0.25 mg; weeks 5–8 advance to 0.5 mg; weeks 9–12 reach 1.0 mg; and weeks 13–16 move to 1.7 mg as the standard maintenance level. Some patients remain effective at intermediate doses like 1.0 or 1.7 mg and never require escalation beyond that point.
This structured approach balances efficacy with tolerability. Each four-week interval gives your system time to stabilize on the current dose, build up receptor sensitivity, and prepare for the next increment. Skipping ahead or slowing down the schedule should only happen under direct medical supervision, as it can disrupt the calibrated balance between benefit and side-effect management.
Why Starting Low Matters for Long-Term Success
Beginning with 0.25 mg sets the foundation for sustained compliance and therapeutic outcomes. Patients who start at the lowest dose report better tolerance, fewer reasons to pause treatment, and greater likelihood of reaching their target weight-loss goals. The gradual introduction also allows your appetite regulation pathways to reset naturally rather than experiencing sudden, jarring hunger suppression.
Research on GLP-1 medications shows that slow titration produces comparable weight loss to faster escalation protocols, but with significantly fewer treatment discontinuations due to side effects. This means the 'slow and steady' approach isn't just comfortable—it's also more effective over the long term because you stay on the medication and complete your therapy course.
PlexusDx Microdose GLP-1: A Personalized Alternative
PlexusDx offers a Microdose GLP-1 Protocol starting at $129 per month, providing compounded semaglutide from licensed 503A pharmacies without flat per-compound pricing or commitment fees. This option serves patients who want to begin at very low concentrations, follow a customized titration timeline, or maintain ongoing microdose therapy for sustained weight management. All PlexusDx medications work in all 50 states and are HSA/FSA eligible.
For patients interested in personalized dosing strategies grounded in genetic insight, PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after first month) to map 14 metabolic pathways and 49 peptides. This test identifies key variants like GLP1R rs6923761 and MC4R rs17782313 that influence your individual GLP-1 response, helping clinicians tailor your starting dose and titration schedule to your unique biology. Your dose may need to go up. Your price won't.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is 0.25 mg the absolute lowest dose of Wegovy available?
Yes, 0.25 mg is Wegovy's entry-level dose and the lowest FDA-approved semaglutide pen strength for chronic weight management. Some compounded GLP-1 providers, including PlexusDx, can create customized concentrations below this threshold for microdose protocols, which may suit patients with extreme sensitivity or specific medical circumstances.
Can I skip the titration schedule and stay on 0.25 mg indefinitely?
Staying at 0.25 mg long-term is possible if you achieve your weight goals or have exceptional sensitivity to higher doses, but clinical evidence suggests most patients need escalation to 1.0 mg or higher for sustained efficacy. Your prescribing clinician can advise whether maintaining a lower dose aligns with your individual metabolic response and health objectives.
How does PlexusDx pricing compare to brand-name Wegovy?
Brand-name Wegovy typically costs $1,000–$1,600 per month out-of-pocket without insurance. PlexusDx compounded semaglutide starts at $149 per month, and the Microdose GLP-1 Protocol begins at $129—both from licensed 503A pharmacies, with no membership fees, no insurance required, and HSA/FSA eligibility. Your dose may need to go up. Your price won't.
What side effects should I expect on the lowest Wegovy dose?
At 0.25 mg, most patients experience mild to no gastrointestinal effects; nausea, constipation, and reduced appetite are usually manageable or absent at this entry level. As you titrate upward, some patients report temporary nausea, vomiting, or constipation that typically resolve within a few days as your body adapts. Staying well-hydrated and eating small, frequent meals help minimize discomfort.
Can the Precision Peptide Genetic Test predict how my body will respond to 0.25 mg?
The Precision Peptide Genetic Test analyzes 150+ genetic insights across 14 metabolic pathways, including GLP1R and MC4R variants, to reveal how your peptide system is primed to respond to GLP-1 therapy. This information helps your clinician anticipate whether you'll respond optimally at lower doses, need faster titration, or benefit from microdose protocols—personalizing your entire treatment journey.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What Is Ozempic Injection Used For?
When You Stop Losing Weight on Ozempic: Understanding the Plateau and What to Do Next